Lung Cancer Biomarkers
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 May 2015) | Viewed by 10638
Special Issue Editor
Interests: targeted cancer therapy; the mechanisms of action of and/or resistance to anticancer agents; and molecular signatures or biomarkers for predicting treatment response or early diagnosis of lung cancers
Special Issue Information
Dear Colleagues,
This special issue on lung cancer biomarkers invites experts to contribute original research reports and review articles that describe recent studies or progress in biomarkers for lung cancer. Biomarkers play a critical role in translational studies of cancers, including early diagnosis, monitoring recurrences, predicting prognosis and treatment responses to anticancer therapy. Various types of biomarkers have been reported, including genomic DNA (mutations, polymorphisms, and DNA methylations), RNA (mRNA and miRNA), proteins and peptides, metabolites, and circulating tumor cells. Those biomarkers can be detected in primary tumor tissues, blood, sputum and other body fluids. The progress in biomarker development also includes development of new methods or technology to improve the sensitivity and specificity of biomarker detections. Some of the biomarkers have already led to a change of concept practice in the clinical management of lung cancers. For example, analysis on EGFR mutations has dramatically improved the response rate of anti-EGFR therapy by identifying potential responders. Thus, studies on biomarkers will have a significant impact on improving cancer patients’ outcomes.
Potential topics include, but are not limited to:
- Biomarkers for early diagnosis of lung cancers, such as improving specificity of CT imaging screening
- Biomarkers for monitoring disease progression or recurrences
- Biomarkers for predicting treatment responses and personalized therapy
- Circulating biomarkers
- Clinical and preclinical evaluations of biomarkers
- Development of methodology and technology to improve specificity and sensitivity,
- Multiple biomarker panels
Professor Bingliang Fang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- early diagnosis
- personalized therapy
- monitoring prognosis and recurrence
- circulating biomarkers
- target therapy
- snps